CBS 2019
CBSMD教育中心
中 文

Other Relevant Articles

Abstract

Recommended Article

Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10 854 patients from the CHAMPION PHOENIX trial Improving the Design of Future PCI Trials for Stable Coronary Artery Disease: JACC State-of-the-Art Review Routinely reported ejection fraction and mortality in clinical practice: where does the nadir of risk lie? Extracorporeal Ultrafiltration for Fluid Overload in Heart Failure: Current Status and Prospects for Further Research Ten-Year Clinical Outcomes From a Trial of Three Limus-Eluting Stents With Different Polymer Coatings in Patients With Coronary Artery Disease Defining Staged Procedures for Percutaneous Coronary Intervention Trials A Guidance Document Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial Major trials in coronary intervention from 2018

Review ArticleApril 2020

JOURNAL:JACC Article Link

COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up

B Bikdeli, MV Madhavan, D Jimenez et al. Keywords: COVID-19; SARS-CoV-2; thrombosis; antithrombotic therapy; anticoagulant; antiplatelet

Full Text PDF